(formerly known as Link-Asia International MedTech Group Limited 環亞國際醫療科技集團有限公司 (Incorporated in the Cayman Islands with limited liability) (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code: 1143) （Stock Code 股份代號：1143） NOTIFICATION LETTER 通知信函 1. Non-Registered Holder means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company L ...

(formerly known as Link-Asia International MedTech Group Limited 環亞國際醫療科技集團有限公司 (Incorporated in the Cayman Islands with limited liability) (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code: 1143) （Stock Code 股份代號：1143） NOTIFICATION LETTER 通知信函 If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communication ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 通 告 全部或任何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （前稱環亞國際醫療科技集團有限公司） （於開曼群島註冊成立的有限公司） （股份代號：1143） 股 東 週 年 大 會 通 告 茲 通 告 中 國 儲 能 科 技 發 展 有 限 公 司（「本 公 司」）將 於 二 零 二 五 年 六 月 二 十 日（星 期 五）上 午 十 時 正 假 座 香 港 皇 后 大 道 中99號 中 環 中 心59樓5906-5912室 舉 行 股 東 週 年 大 會（「大 會」），以 考 慮 及 酌 情 通 過（不 論 有 否 修 訂）以 下 決 議 案 為 本 公 司 普 通 決 議 案： 普 通 決 議 案 「有 關 期 間」乃 指 由 本 決 議 案 獲 通 過 之 日 起 至 下 列 最 早 日 期 止 期 間： – 3 – – 1 – 1. 省 覽 ...

此 乃 要 件 請 即 處 理 （前稱環亞國際醫療科技集團有限公司） （於開曼群島註冊成立的有限公司） （股份代號：1143） 建 議 (1)發 行 及 購 回 股 份 的 一 般 授 權 閣 下 如 對 本 通 函 或 應 採 取 之 行 動 有 任 何 疑 問，應 諮 詢 閣 下 的 持 牌 證 券 交 易 商 或 其 他 註 冊 證 券 交 易 商、銀 行 經 理、律 師、專 業 會 計 師 或 其 他 專 業 顧 問。 閣 下 如 已 將 名 下 的 中 國 儲 能 科 技 發 展 有 限 公 司（「本 公 司」）的 股 份 全 部 出 售 或 轉 讓，應 立 即 將 本 通 函 及 隨 附 的 代 表 委 任 表 格 送 交 買 主 或 承 讓 人，或 經 手 買 賣 或 轉 讓 的 銀 行、持 牌 證 券 交 易 商 或 其 他 代 理 商，以 便 轉 交 買 主 或 承 讓 人。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 函 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 ...

Financial Performance - Revenue from continuing operations decreased from approximately HK$491.6 million in 2023 to approximately HK$479.3 million in 2024, representing a decline of about 2.3%[14]. - Profit for the year from continuing operations increased from HK$4.9 million in 2023 to HK$6.5 million in 2024, a growth of approximately 32.7%[7]. - Profit attributable to owners of the Company rose from HK$5.3 million in 2023 to HK$8.0 million in 2024, marking an increase of approximately 50.9%[7]. - For the year ended December 31, 2024, the Group recorded total revenue of HK$479.3 million, a decrease from HK$491.6 million in 2023[74]. - Gross profit decreased by 6.2% from HK$131.8 million to HK$123.6 million, with a slight decline in gross profit margin by 1.0% due to changes in product mix[83]. - Other income rose from approximately HK$13.1 million in 2023 to approximately HK$17.9 million in 2024, primarily due to increased interest income and compensation related to intangible assets[89]. Revenue Segmentation - The Group generated approximately HK$11.9 million in revenue from real estate supply chain services and energy storage products segments in 2024[15]. - The EMS segment revenue increased by approximately HK$10.9 million in 2024, primarily due to growth in the European market[22]. - For the year ended December 31, 2024, the revenue from the Electronic Manufacturing Services (EMS) segment increased by 2.5% to HK$455.1 million, compared to HK$444.2 million in 2023[27]. - Revenue from the Distribution segment decreased by 98.0% to HK$0.2 million, down from HK$10.4 million in 2023, due to declining demand for business telephone systems in North America[27]. - Revenue from the Real Estate Supply Chain Services and Energy Storage Products (RES and ESP) segment decreased by approximately 40.1% to HK$11.9 million, down from HK$19.8 million in 2023, primarily due to a decrease in the energy storage business[32]. Financial Position - As of December 31, 2024, the Group had bank and cash balances totaling approximately HK$312.1 million, up from HK$271.6 million in 2023[24]. - Total assets increased from HK$776.4 million in 2023 to HK$880.1 million in 2024, reflecting a growth of approximately 13.3%[7]. - Total liabilities rose from HK$287.7 million in 2023 to HK$343.3 million in 2024, an increase of approximately 19.4%[7]. - The current ratio remained healthy at 2.7 times as of December 31, 2024, compared to 2.6 times in 2023[103]. Cash Flow and Investments - The Group's securities and other assets investment contributed revenue of approximately HK$19.0 million, down from HK$27.3 million in 2023[33]. - The Group plans to actively seek investment opportunities to broaden its revenue base and enhance future financial performance[120]. - Capital expenditure for 2024 was HK$2.5 million, with capital commitments of HK$1.0 million as of December 31, 2024, primarily related to the acquisition of plant and machinery[109]. Credit and Loan Management - The Group's money lending operations generated revenue of approximately HK$0.2 million, accounting for approximately 0.03% of overall revenue, with an operating profit of approximately HK$0.5 million[36]. - The Group's money lending business is focused on unsecured loans, with all loans collected during the year at an interest rate of 10% per annum[35]. - The Group maintains strict credit policies and controls to mitigate credit risks, including thorough credit assessments and compliance with anti-money laundering regulations[45]. - The Group's impairment loss assessments are based on expected credit loss (ECL) requirements under HKFRS 9, regularly evaluating loans and interest receivables[54]. - The management continuously monitors the credit quality of each borrower to minimize exposure to credit risk[60]. Share Options and Equity - The 2020 Share Option Scheme was adopted on March 10, 2020, replacing the 2010 Share Option Scheme[123]. - On January 28, 2021, 35,671,850 share options were granted to certain Directors and employees under the 2020 Share Option Scheme[128]. - The company proposed the adoption of the 2023 Share Option Scheme and 2023 Share Award Plan at the 2023 AGM, which was approved by shareholders[130]. - The maximum entitlement for each participant under the 2023 Share Award Plan is capped at 1% of the issued share capital of the Company within any 12-month period[145]. - The company terminated the 2020 Share Option Scheme during the 2023 AGM[130]. Corporate Governance - The Board of Directors consists of five executive directors and three independent non-executive directors, with independent directors accounting for over one-third of the Board[198]. - The company has complied with the Corporate Governance Code throughout the year ended December 31, 2024, except for deviations in code provisions C.2.1 and C.1.6[190]. - The company does not have a designated chief executive officer, which deviates from code provision C.2.1[191]. - The company has adopted the Model Code for Securities Transactions by Directors and confirmed compliance by all directors for the year ended December 31, 2024[197].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券之邀請或要約。 （前稱環亞國際醫療科技集團有限公司） （於開曼群島註冊成立的有限公司） （股份代號：1143） 有關 I .建議按於記錄日期每持有一(1)股現有股份獲發 兩(2)股供股股份的基準進行供股； II .建議更改每手買賣單位；及 III .有關轉讓分銷權的主要交易 茲提述中國儲能科技發展有限公司（「本公司」）日期為二零二四年十二月十三日、 二零二五年一月二日、二零二五年一月七日、二零二五年二月四日、二零二五年 三月四日及二零二五年三月二十六日內容有關（ 其中包括 ）供股、更改每手買賣單 位、配售事項及轉讓的公告（「該等公告」）。除文義另有所指外，本公告所用詞彙 與該等公告所界定者具相同涵義。 – 1 – 進一步延遲寄發通函 誠如該等公告所披露，載有（ 其中包括 ）(i)供股、配售 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company reported total revenue of HKD 479,317,000, a decrease of 2.4% compared to HKD 491,597,000 for the previous year[2] - The gross profit for the fiscal year 2024 was HKD 123,601,000, down from HKD 131,755,000 in 2023, representing a decline of 6.2%[2] - The operating expenses increased to HKD 99,076,000 in 2024 from HKD 85,599,000 in 2023, marking an increase of 15.7%[2] - The net profit from continuing operations for the fiscal year 2024 was HKD 6,457,000, compared to HKD 4,881,000 in 2023, reflecting a growth of 32.3%[3] - The company reported a basic earnings per share of HKD 3.87 for continuing operations, up from HKD 3.06 in the previous year, indicating an increase of 26.5%[3] - The company reported a net profit of HKD 6,328,000 for the year ending December 31, 2024, compared to HKD 5,165,000 in 2023, representing a year-over-year increase of approximately 22.5%[4] - Total comprehensive income for the year was HKD (5,267,000), a significant increase from HKD (2,985,000) in the previous year, indicating a worsening in comprehensive income[4] Revenue Breakdown - Revenue from external customers for the year ended December 31, 2024, was HKD 479,317,000, compared to HKD 491,597,000 for the year ended December 31, 2023, reflecting a slight decrease[19] - The revenue from electronic manufacturing services was HKD 455,081,000 for the year ended December 31, 2024, compared to HKD 444,171,000 for the previous year, indicating an increase[19] - Revenue from major customer A was HKD 230,641,000 in 2024, slightly down from HKD 235,380,000 in 2023, indicating a decline of about 2.9%[21] - Revenue from the United States market increased from HKD 99,263,000 in 2023 to HKD 112,459,000 in 2024, reflecting a growth of approximately 13.3%[22] - Revenue from the Chinese market (including Hong Kong) decreased from HKD 84,928,000 in 2023 to HKD 56,729,000 in 2024, a decline of about 33.2%[22] - Revenue from Thailand increased significantly from HKD 13,034,000 in 2023 to HKD 27,103,000 in 2024, representing a growth of approximately 108.5%[22] - Revenue from Switzerland decreased from HKD 62,894,000 in 2023 to HKD 55,882,000 in 2024, a decline of about 11.1%[22] Expenses and Costs - Research and development expenses for the fiscal year 2024 were HKD 12,835,000, slightly down from HKD 13,092,000 in 2023, a decrease of 2.0%[2] - The total cost of sales for 2024 was HKD 355,716,000, a minor decrease from HKD 359,842,000 in 2023, reflecting a reduction of 1.6%[2] - Selling and distribution expenses were HKD 38,400,000, representing about 8.0% of total revenue, up from 7.4% in 2023[52] - Administrative expenses rose to HKD 99,100,000, accounting for 20.7% of total revenue, compared to 17.4% in 2023[53] Assets and Liabilities - The company's total assets reached HKD 880,137,000 in 2024, up from HKD 776,418,000 in 2023, reflecting a growth of about 13.4%[5] - Current assets increased to HKD 801,491,000 in 2024, compared to HKD 705,931,000 in 2023, marking a rise of approximately 13.5%[5] - Non-current assets totaled HKD 70,487,000 in 2024, down from HKD 78,646,000 in 2023, indicating a decrease of about 10.3%[5] - Total liabilities amounted to HKD 391,412,000 in 2024, an increase from HKD 239,533,000 in 2023, representing a rise of about 63.4%[9] - The company's equity attributable to shareholders was HKD 486,663,000 in 2024, compared to HKD 536,531,000 in 2023, showing a decline of approximately 9.3%[7] Strategic Initiatives - The company plans to expand its market presence and invest in new technologies to drive future growth[2] - The company has indicated a focus on strategic acquisitions to enhance its competitive position in the market[2] - The company is focusing on technological innovation and optimizing business models to capture opportunities in the energy storage market driven by policy and market demand[70] - The company is closely monitoring market conditions and will adjust its business development strategies as necessary in response to global economic challenges[71] - The company aims to achieve a revenue growth target of 15% year-over-year in the upcoming fiscal year[87] Governance and Compliance - The consolidated financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards issued by the Hong Kong Institute of Certified Public Accountants[10] - The group has adopted new and revised Hong Kong Financial Reporting Standards effective from January 1, 2024, which may impact future financial reporting[12] - The audit committee consists of three independent non-executive directors and is responsible for overseeing the financial reporting process and internal controls[83] - The company has complied with the corporate governance code, except for deviations noted in specific rules regarding the separation of roles between the chairman and CEO[79][80] Future Outlook - Future outlook indicates a focus on expanding market presence and enhancing product offerings to drive growth[87] - The company is investing in new product development and technological advancements to stay competitive in the industry[87] - Ongoing research and development efforts are expected to yield new innovations within the next 12 months[87] - User engagement metrics have improved by 20%, indicating a positive trend in customer satisfaction[87]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 更改董事會會議日期 茲提述中國儲能科技發展有限公司（「本公司」）日期為二零二五年三月十四年的公 告，內容有關本公司將於二零二五年三月二十八日（ 星期五 ）舉行董事（「董事」）會 （「董事會」）會議，藉以（ 其中包括 ）考慮批准本公司及其附屬公司截至二零二四年 十二 月三十 一日 止年度 的全年 業績（「全年 業績」）以及 考慮建 議派發 末期股 息（ 如 有 ）。 由 於 需 要 更 多 時 間 落 實 全 年 業 績 ， 故 董 事 會 謹 此 宣 佈 ， 董 事 會 會 議 改 於 二 零二五年三月三十一日（ 星期一 ）舉行。 承董事會命 中國儲能科技發展有限公司 （前稱環亞國際醫療科技集團有限公司） （於開曼群島註冊成立的有限公司） （股份代號：1143） 主席兼執行董事 林代聯 於 本 公 告 日 期 ， 董 事 會 成 員 包 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券之邀請或要約。 （前稱環亞國際醫療科技集團有限公司） （於開曼群島註冊成立的有限公司） （股份代號：1143） 有關 I .建議按於記錄日期每持有一(1)股現有股份獲發 兩(2)股供股股份的基準進行供股； II .建議更改每手買賣單位；及 III .有關轉讓分銷權的主要交易 進一步延遲寄發通函及經修訂時間表 本公司之聯席配售代理 茲提述中國儲能科技發展有限公司（「本公司」）日期為二零二四年十二月十三日、 二零二五年一月二日、二零二五年一月七日、二零二五年二月四日及二零二五年 三月四日內容有關（ 其中包括 ）供股、更改每手買賣單位、配售事項及轉讓的公告 （「該等公告」）。除文義另有所指外，本公告所用詞彙與該等公告所界定者具相同 涵義。 進一步延遲寄發通函 誠如該等公告所披露，載有（ 其中包括 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 承董事會命 中國儲能科技發展有限公司 主席兼執行董事 林代聯 香港，二零二五年三月十四日 （前稱環亞國際醫療科技集團有限公司） （於開曼群島註冊成立的有限公司） （股份代號：1143） 董事會會議日期 中國儲能科技發展有限公司（「本公司」）董事會（「董事會」）謹此公佈，本公司將於 二零二五年三月二十八日（ 星期五 ）舉行董事會會議，藉以（ 其中包括 ）考慮及批准 本公司及其附屬公司截至二零二四年十二月三十一日止年度的全年業績、建議派 發末期股息（ 如有 ）及處理任何其他事項。 於 本 公 告 日 期 ， 董 事 會 成 員 包 括 執 行 董 事 林 代 聯 先 生（ 主 席 ）、 卞 蘇 蘭 女 士 、 劉志威先生、王琪先生及林曉珊女士；獨立非執行董事李慧武先生、胡子敬先生 及張秀琳女士。 ...